3. ASIMA (1964-1975) Creación y primera etapa de desarrollo
3.1 Primeras gestiones para la creación de ASIMA
0.7 µM purified Ppz1 or Ppz1R451L was mixed with either 2.1 µM hexameric
Hsp104 or Hsp104A503S (purified as reported)(207) and 4 mM ATP (pH 7.5) in Buffer A
(20 mM Tris-HCl pH 7.5, 100 mM KCl, 5 mM DTT, 0.1 mM EGTA, 10% glycerol, 20µg/ml BSA, 0.005% Triton X-100, 10 mM MnCl2). 10mM pNPP reagent was added, at the
concentration recommended in manufacturer instructions (BioAssay Systems Cat. No. POPN-500). Absorbance at 405nm was measured every 30 seconds for 15 minutes by Tecan Safire2 at room temperature.
120
BIBLIOGRAPHY
1. C. M. Dobson, Principles of protein folding, misfolding and aggregation. Semin
Cell Dev Biol15, 3-16 (2004).
2. E. T. Wang et al., Alternative isoform regulation in human tissue transcriptomes.
Nature456, 470-476 (2008).
3. A. K. Dunker, I. Silman, V. N. Uversky, J. L. Sussman, Function and structure of inherently disordered proteins. Current opinion in structural biology18, 756-764 (2008).
4. T. Vavouri, J. I. Semple, R. Garcia-Verdugo, B. Lehner, Intrinsic protein disorder and interaction promiscuity are widely associated with dosage sensitivity. Cell
138, 198-208 (2009).
5. C. B. Anfinsen, Principles that govern the folding of protein chains. Science181, 223-230 (1973).
6. C. B. Anfinsen, E. Haber, M. Sela, F. H. White, Jr., The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain.
Proceedings of the National Academy of Sciences of the United States of
America47, 1309-1314 (1961).
7. B. Robson, R. H. Pain, Analysis of the code relating sequence to conformation in proteins: possible implications for the mechanism of formation of helical regions.
Journal of molecular biology58, 237-259 (1971).
8. K. A. Dill, Theory for the folding and stability of globular proteins. Biochemistry
24, 1501-1509 (1985).
9. V. R. Agashe, M. C. R. Shastry, J. B. Udgaonkar, Initial hydrophobic collapse in the folding of barstar. Nature377, 754-757 (1995).
10. J. N. Onuchic, Z. Luthey-Schulten, P. G. Wolynes, Theory of protein folding: the energy landscape perspective. Annual review of physical chemistry48, 545-600 (1997).
11. R. J. Ellis, A. P. Minton, Protein aggregation in crowded environments. Biol Chem387, 485-497 (2006).
12. A. Gershenson, L. M. Gierasch, A. Pastore, S. E. Radford, Energy landscapes of functional proteins are inherently risky. Nat Chem Biol10, 884-891 (2014). 13. S. W. Englander, L. Mayne, Z.-Y. Kan, W. Hu, Protein Folding—How and Why:
By Hydrogen Exchange, Fragment Separation, and Mass Spectrometry. Annual
Review of Biophysics45, 135-152 (2016).
14. I. Amm, T. Sommer, D. H. Wolf, Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. Biochimica et biophysica acta1843, 182-196 (2014).
15. F. U. Hartl, A. Bracher, M. Hayer-Hartl, Molecular chaperones in protein folding and proteostasis. Nature475, 324-332 (2011).
16. F. U. Hartl, M. Hayer-Hartl, Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein. Science295, 1852-1858 (2002).
17. J. Buchner, Supervising the fold: functional principles of molecular chaperones.
Faseb j10, 10-19 (1996).
18. J. L. Johnson, E. A. Craig, Protein folding in vivo: unraveling complex pathways.
Cell90, 201-204 (1997).
19. W. E. Balch, R. I. Morimoto, A. Dillin, J. W. Kelly, Adapting proteostasis for disease intervention. Science319, 916-919 (2008).
121
20. B. Beatrix, H. Sakai, M. Wiedmann, The alpha and beta subunit of the nascent polypeptide-associated complex have distinct functions. The Journal of biological
chemistry275, 37838-37845 (2000).
21. T. Hesterkamp, S. Hauser, H. Lutcke, B. Bukau, Escherichia coli trigger factor is a prolyl isomerase that associates with nascent polypeptide chains. Proceedings
of the National Academy of Sciences of the United States of America93, 4437-
4441 (1996).
22. C. M. Dobson, M. Karplus, The fundamentals of protein folding: bringing together theory and experiment. Current opinion in structural biology 9, 92-101 (1999). 23. D. Balchin, M. Hayer-Hartl, F. U. Hartl, In vivo aspects of protein folding and
quality control. Science353, aac4354 (2016).
24. M. P. Castanie-Cornet, N. Bruel, P. Genevaux, Chaperone networking facilitates protein targeting to the bacterial cytoplasmic membrane. Biochimica et
biophysica acta1843, 1442-1456 (2014).
25. E. M. Clerico, J. M. Tilitsky, W. Meng, L. M. Gierasch, How hsp70 molecular machines interact with their substrates to mediate diverse physiological functions. Journal of molecular biology427, 1575-1588 (2015).
26. F. Willmund et al., The cotranslational function of ribosome-associated Hsp70 in eukaryotic protein homeostasis. Cell152, 196-209 (2013).
27. M. P. Mayer, Hsp70 chaperone dynamics and molecular mechanism. Trends in
biochemical sciences38, 507-514 (2013).
28. M. Taipale et al., Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell150, 987-1001 (2012).
29. M. Taipale, D. F. Jarosz, S. Lindquist, HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nature reviews. Molecular cell biology11, 515- 528 (2010).
30. A. Shemorry, C. S. Hwang, A. Varshavsky, Control of protein quality and
stoichiometries by N-terminal acetylation and the N-end rule pathway. Molecular cell50, 540-551 (2013).
31. J. W. Heck, S. K. Cheung, R. Y. Hampton, Cytoplasmic protein quality control degradation mediated by parallel actions of the E3 ubiquitin ligases Ubr1 and San1. Proceedings of the National Academy of Sciences of the United States of
America107, 1106-1111 (2010).
32. J. R. Glover, S. Lindquist, Hsp104, Hsp70, and Hsp40: A Novel Chaperone System that Rescues Previously Aggregated Proteins. Cell94, 73-82 (1998). 33. A. Mogk, E. Kummer, B. Bukau, Cooperation of Hsp70 and Hsp100 chaperone
machines in protein disaggregation. Frontiers in molecular biosciences2, 22 (2015).
34. M. Zolkiewski, ClpB cooperates with DnaK, DnaJ, and GrpE in suppressing protein aggregation. A novel multi-chaperone system from Escherichia coli. The
Journal of biological chemistry274, 28083-28086 (1999).
35. J. Shorter, The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell- free system. PLoS One6, e26319 (2011).
36. A. B. Singleton et al., alpha-Synuclein locus triplication causes Parkinson's disease. Science302, 841 (2003).
37. M. C. Chartier-Harlin et al., Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (London, England)364, 1167-1169 (2004).
122
38. P. Ibanez et al., Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (London, England)364, 1169-1171 (2004). 39. C. O. Hanemann, H. W. Muller, Pathogenesis of Charcot-Marie-Tooth 1A
(CMT1A) neuropathy. Trends in neurosciences21, 282-286 (1998).
40. B. S. Shastry, Overexpression of genes in health and sickness. A bird's eye view.
Comparative biochemistry and physiology. Part B, Biochemistry & molecular
biology112, 1-13 (1995).
41. R. S. N. Fehrmann et al., Gene expression analysis identifies global gene dosage sensitivity in cancer. Nature genetics47, 115-125 (2015).
42. R. Sopko et al., Mapping pathways and phenotypes by systematic gene overexpression. Molecular cell21, 319-330 (2006).
43. J. M. Sheltzer, A. Amon, The aneuploidy paradox: costs and benefits of an incorrect karyotype. Trends in genetics : TIG27, 446-453 (2011).
44. E. M. Torres, B. R. Williams, A. Amon, Aneuploidy: cells losing their balance.
Genetics179, 737-746 (2008).
45. M. Durrbaum, Z. Storchova, Effects of aneuploidy on gene expression: implications for cancer. The FEBS journal283, 791-802 (2016).
46. E. M. Torres et al., Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science317, 916-924 (2007).
47. A. M. Deutschbauer et al., Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast. Genetics169, 1915-1925 (2005).
48. M. S. Cheon et al., Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part II).
Amino acids24, 119-125 (2003).
49. M. S. Cheon et al., Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part III).
Amino acids24, 127-134 (2003).
50. M. S. Cheon et al., Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part I).
Amino acids24, 111-117 (2003).
51. M. S. Cheon, K. S. Shim, S. H. Kim, A. Hara, G. Lubec, Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part IV). Amino acids25, 41-47 (2003).
52. L. Whitesell, S. L. Lindquist, HSP90 and the chaperoning of cancer. Nat Rev
Cancer5, 761-772 (2005).
53. J. Lejeune, M. Gautier, R. Turpin, [Study of somatic chromosomes from 9 mongoloid children]. Comptes rendus hebdomadaires des seances de
l'Academie des sciences248, 1721-1722 (1959).
54. R. Lyle, C. Gehrig, C. Neergaard-Henrichsen, S. Deutsch, S. E. Antonarakis, Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res14, 1268-1274 (2004).
55. M. Hattori et al., The DNA sequence of human chromosome 21. Nature 405, 311-319 (2000).
56. S. E. Antonarakis, R. Lyle, E. T. Dermitzakis, A. Reymond, S. Deutsch,
Chromosome 21 and down syndrome: from genomics to pathophysiology. Nature
reviews. Genetics5, 725-738 (2004).
57. J. B. Leverenz, M. A. Raskind, Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp
123
58. K. E. Wisniewski, H. M. Wisniewski, G. Y. Wen, Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Annals of
neurology17, 278-282 (1985).
59. G. Marucci et al., Amyotrophic lateral sclerosis with mutation of the Cu/Zn superoxide dismutase gene (SOD1) in a patient with Down syndrome.
Neuromuscular disorders : NMD17, 673-676 (2007).
60. H. Rajagopalan, C. Lengauer, Aneuploidy and cancer. Nature432, 338-341 (2004).
61. G. J. Kops, B. A. Weaver, D. W. Cleveland, On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer5, 773-785 (2005).
62. M. Giam, G. Rancati, Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell division10, 3 (2015).
63. J. J. Siegel, A. Amon, New insights into the troubles of aneuploidy. Annual review
of cell and developmental biology28, 189-214 (2012).
64. N. Pavelka, G. Rancati, R. Li, Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer. Current opinion in cell biology22, 809-815 (2010).
65. F. Bunz et al., Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer research62, 1129-1133 (2002).
66. H. Hasle, I. H. Clemmensen, M. Mikkelsen, Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet (London, England)355, 165-169 (2000).
67. B. A. Weaver, D. W. Cleveland, Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer research67, 10103-10105 (2007).
68. B. A. Weaver, A. D. Silk, C. Montagna, P. Verdier-Pinard, D. W. Cleveland, Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer cell11, 25-36 (2007).
69. I. M. Shih et al., Top-down morphogenesis of colorectal tumors. Proceedings of
the National Academy of Sciences of the United States of America98, 2640-
2645 (2001).
70. N. Pavelka et al., Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature468, 321-325 (2010).
71. A. H. Yona et al., Chromosomal duplication is a transient evolutionary solution to stress. Proceedings of the National Academy of Sciences of the United States of
America109, 21010-21015 (2012).
72. P. Duesberg, C. Rausch, D. Rasnick, R. Hehlmann, Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proceedings of the National
Academy of Sciences of the United States of America95, 13692-13697 (1998).
73. A. Fabarius, R. Hehlmann, P. H. Duesberg, Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer
genetics and cytogenetics143, 59-72 (2003).
74. A. J. Lee et al., Chromosomal instability confers intrinsic multidrug resistance.
Cancer research71, 1858-1870 (2011).
75. G. Chen et al., Targeting the adaptability of heterogeneous aneuploids. Cell160, 771-784 (2015).
76. S. A. Armstrong et al., MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature genetics30, 41-47 (2002). 77. C. C. O'Connor, Human chromosome translocations and cancer. Nature
124
78. J. D. Rowley, Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature243, 290-293 (1973).
79. J. D. Rowley, Ph1-positive leukaemia, including chronic myelogenous leukaemia.
Clinics in haematology9, 55-86 (1980).
80. J. Groffen et al., Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell36, 93-99 (1984).
81. T. G. Lugo, A. M. Pendergast, A. J. Muller, O. N. Witte, Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science247, 1079- 1082 (1990).
82. D. M. Miller, S. D. Thomas, A. Islam, D. Muench, K. Sedoris, c-Myc and cancer metabolism. Clinical cancer research : an official journal of the American
Association for Cancer Research18, 5546-5553 (2012).
83. J. Gearhart, E. E. Pashos, M. K. Prasad, Pluripotency redux--advances in stem- cell research. N Engl J Med357, 1469-1472 (2007).
84. R. Taub et al., Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.
Proceedings of the National Academy of Sciences of the United States of
America79, 7837-7841 (1982).
85. R. Dalla-Favera et al., Human c-myc onc gene is located on the region of
chromosome 8 that is translocated in Burkitt lymphoma cells. Proceedings of the
National Academy of Sciences of the United States of America79, 7824-7827
(1982).
86. J. M. Adams et al., Transcriptionally active DNA region that rearranges frequently in murine lymphoid tumors. Proceedings of the National Academy of Sciences of
the United States of America79, 6966-6970 (1982).
87. S. Crews, R. Barth, L. Hood, J. Prehn, K. Calame, Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in
plasmacytomas. Science218, 1319-1321 (1982).
88. P. H. Hamlyn, T. H. Rabbitts, Translocation joins c-myc and immunoglobulin gamma 1 genes in a Burkitt lymphoma revealing a third exon in the c-myc oncogene. Nature304, 135-139 (1983).
89. J. Battey et al., The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell34, 779-787 (1983). 90. G. F. Hollis et al., A variant translocation places the lambda immunoglobulin
genes 3' to the c-myc oncogene in Burkitt's lymphoma. Nature 307, 752-755 (1984).
91. J. B. a. M. F. E. Mitelman F, "Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (2016).
92. S. Janz, M. Potter, C. S. Rabkin, Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes, chromosomes &
cancer36, 211-223 (2003).
93. D. S. Latchman, Transcription factors: an overview. The international journal of
biochemistry & cell biology29, 1305-1312 (1997).
94. D. B. Nikolov, S. K. Burley, RNA polymerase II transcription initiation: a structural view. Proceedings of the National Academy of Sciences of the United States of
America94, 15-22 (1997).
95. E. H. Davidson, Emerging properties of animal gene regulatory networks. Nature
125
96. I. S. Peter, E. H. Davidson, Evolution of gene regulatory networks controlling body plan development. Cell144, 970-985 (2011).
97. D. R. Green, G. Kroemer, Cytoplasmic functions of the tumour suppressor p53.
Nature458, 1127-1130 (2009).
98. B. Mayr, M. Montminy, Transcriptional regulation by the phosphorylation- dependent factor CREB. Nature reviews. Molecular cell biology2, 599-609 (2001).
99. M. G. Rosenfeld, V. V. Lunyak, C. K. Glass, Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev20, 1405-1428 (2006).
100. M. A. Resnick, A. Inga, Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proceedings of the
National Academy of Sciences of the United States of America100, 9934-9939
(2003).
101. S. Garritano, A. Inga, F. Gemignani, S. Landi, More targets, more pathways and more clues for mutant p53. Oncogenesis2, e54 (2013).
102. F. Spitz, E. E. Furlong, Transcription factors: from enhancer binding to developmental control. Nature reviews. Genetics13, 613-626 (2012).
103. J. C. Nixon, J. Rajaiya, C. F. Webb, Mutations in the DNA-binding domain of the transcription factor Bright act as dominant negative proteins and interfere with immunoglobulin transactivation. The Journal of biological chemistry279, 52465- 52472 (2004).
104. S. Kato et al., Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proceedings of the National Academy of Sciences of the
United States of America100, 8424-8429 (2003).
105. E. Balzi, M. Wang, S. Leterme, L. Van Dyck, A. Goffeau, PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1. The Journal of biological chemistry269, 2206-2214 (1994). 106. G. H. Rank, N. T. Bech-Hansen, Single nuclear gene inherited cross resistance
and collateral sensitivity to 17 inhibitors of mitochondrial function in S. cerevisiae.
Mol Gen Genet126, 93-102 (1973).
107. G. H. Rank, A. J. Robertson, K. L. Phillips, Modification and inheritance of pleiotropic cross resistance and collateral sensitivity in Saccharomyces cerevisiae. Genetics, 783-793 (1975).
108. E. Carvajal, H. B. van den Hazel, A. Cybularz-Kolaczkowska, E. Balzi, A.
Goffeau, Molecular and phenotypic characterization of yeast PDR1 mutants that show hyperactive transcription of various ABC multidrug transporter genes. Mol
Gen Genet256, 406-415 (1997).
109. C. Gao, L. Wang, E. Milgrom, W. C. Shen, On the mechanism of constitutive Pdr1 activator-mediated PDR5 transcription in Saccharomyces cerevisiae: evidence for enhanced recruitment of coactivators and altered nucleosome structures. The Journal of biological chemistry279, 42677-42686 (2004). 110. S. H. Lecker, A. L. Goldberg, W. E. Mitch, Protein degradation by the ubiquitin-
proteasome pathway in normal and disease states. Journal of the American
Society of Nephrology : JASN17, 1807-1819 (2006).
111. K. L. Rock et al., Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.
126
112. C. He, D. J. Klionsky, Regulation mechanisms and signaling pathways of autophagy. Annual review of genetics43, 67-93 (2009).
113. H. Nakatogawa, K. Suzuki, Y. Kamada, Y. Ohsumi, Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nature reviews. Molecular cell
biology10, 458-467 (2009).
114. D. H. Wolf, W. Hilt, The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochimica et biophysica acta1695, 19-31 (2004).
115. D. H. Wolf, T. Sommer, W. Hilt, Death gives birth to life: the essential role of the ubiquitin-proteasome system in biology. Biochimica et biophysica acta1695, 1-2 (2004).
116. M. H. Glickman, A. Ciechanover, The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological reviews82, 373-428 (2002).
117. J. Boehringer et al., Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation. The Biochemical journal
448, 55-65 (2012).
118. A. M. Cuervo, E. Wong, Chaperone-mediated autophagy: roles in disease and aging. Cell research24, 92-104 (2014).
119. H. L. Chiang, S. R. Terlecky, C. P. Plant, J. F. Dice, A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science
246, 382-385 (1989).
120. T. Yorimitsu, D. J. Klionsky, Autophagy: molecular machinery for self-eating. Cell
death and differentiation12 Suppl 2, 1542-1552 (2005).
121. M. H. Polymeropoulos et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science276, 2045-2047 (1997).
122. D. Snead, D. Eliezer, Alpha-synuclein function and dysfunction on cellular membranes. Experimental neurobiology23, 292-313 (2014).
123. M. G. Spillantini et al., Alpha-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
124. M. G. Spillantini, Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism & related disorders5, 157-162 (1999).
125. M. Goedert, M. G. Spillantini, K. Del Tredici, H. Braak, 100 years of Lewy pathology. Nature reviews. Neurology9, 13-24 (2013).
126. R. Kruger et al., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature genetics 18, 106-108 (1998).
127. J. J. Zarranz et al., The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of neurology55, 164-173 (2004). 128. W. Dauer, S. Przedborski, Parkinson's disease: mechanisms and models.
Neuron39, 889-909 (2003).
129. T. M. Dawson, V. L. Dawson, Molecular Pathways of Neurodegeneration in Parkinson's Disease. Science302, 819-822 (2003).
130. D. Eliezer, E. Kutluay, R. Bussell, Jr., G. Browne, Conformational properties of alpha-synuclein in its free and lipid-associated states. Journal of molecular
biology307, 1061-1073 (2001).
131. A. B. Mantsyzov et al., A maximum entropy approach to the study of residue- specific backbone angle distributions in alpha-synuclein, an intrinsically disordered protein. Protein science : a publication of the Protein Society23, 1275-1290 (2014).
127
132. L. Stefanis, alpha-Synuclein in Parkinson's disease. Cold Spring Harbor
perspectives in medicine2, a009399 (2012).
133. T. Bartels et al., The N-terminus of the intrinsically disordered protein alpha- synuclein triggers membrane binding and helix folding. Biophysical journal99, 2116-2124 (2010).
134. D. Ebrahimi-Fakhari, L. Wahlster, P. J. McLean, Protein degradation pathways in Parkinson's disease: curse or blessing. Acta neuropathologica124, 153-172 (2012).
135. M. Martinez-Vicente et al., Dopamine-modified alpha-synuclein blocks
chaperone-mediated autophagy. The Journal of clinical investigation118, 777- 788 (2008).
136. S. K. Mak, A. L. McCormack, A. B. Manning-Bog, A. M. Cuervo, D. A. Di Monte,